Industry groups are looking to push government drug price negotiation and PBM reforms into a massive Republican domestic ...

Praxis reported that its lead small molecule program failed a Phase 3 study on Friday morning, sending its stock price down ...

CHMP recommends approval of Regeneron's Lynozyfic, Krystal's Vyjuvek, Accord's trabectedin, Takeda's Deqsiga, and 16 label ...

BridgeBio Oncology Therapeutics to go public via merger with Helix Acquisition Corp. II SPAC, led by Bihua Chen's Cormorant, ...

Infectious disease professionals, bracing for an overhaul of the CDC's vaccine advisory group, are in discussions to stand up ...

William Pao, former Roche R&D leader and Pfizer CDO, now leads Revelio Therapeutics (formerly Launchpad) as CEO, joins ...

More than a month after its most recent scheduled meeting was postponed, a panel advising the government on a federal ...

Something changed for Bill Anderson when he turned 50. He was ascending the ranks of Roche’s Genentech, but the Texas native ...

John Coster, CMS' senior technical advisor for the Medicare drug rebate and negotiation group, told Endpoints News that he's ...

Kallyope's Phase 2 obesity trial shows K-757 and K-833 combo achieved 2.9% weight loss vs 0.2% for placebo. Results fall ...

Vertex Pharmaceuticals exits liver disease gene editing program with Verve Therapeutics. Verve continues work on a separate ...

Sorriso Pharmaceuticals presents Phase 1b data for SOR102, an oral bispecific antibody for IBD, showing 40% endoscopic ...